Wegovy 2.4 mg/0.75 mL pre-filled pen

What is Wegovy?

Wegovy contains semaglutide, a human glucagon-like peptide-1 (GLP-1) analogue produced using recombinant DNA technology.

It works as a GLP-1 receptor agonist that helps regulate appetite and calorie intake by acting on areas of the brain involved in appetite regulation.

Wegovy Indication: Who is it for?

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with:

An initial Body Mass Index (BMI) of ≥30 kg/m² (obesity)

A BMI of ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity (such as prediabetes, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

How should I use Wegovy?

Wegovy is administered as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm.

The maintenance dose of 2.4 mg is reached through a gradual 16-week dose escalation period to reduce gastrointestinal side effects.

Dose escalation schedule:

Weeks 1 to 4: 0.25 mg once weekly

Weeks 5 to 8: 0.5 mg once weekly

Weeks 9 to 12: 1 mg once weekly

Weeks 13 to 16: 1.7 mg once weekly

Week 17 and onwards: 2.4 mg once weekly (maintenance dose)

Inject at any time of day, with or without meals.

What should I do if I miss a dose?

If a dose is missed, it should be administered as soon as possible within 5 days after the missed dose.

If more than 5 days have passed, skip the missed dose and resume the regular schedule.

The day of weekly administration can be changed, if necessary, as long as the time between two doses is at least 3 days (>72 hours).

Important Information

Not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease.

Not recommended for patients with severe hepatic impairment; use cautiously in patients with mild to moderate hepatic impairment.

May cause gastrointestinal adverse reactions that can lead to dehydration. Patients should take precautions to avoid fluid depletion.

Acute pancreatitis has been observed with GLP-1 receptor agonists. Discontinue if pancreatitis is suspected.

Should not be used as a substitute for insulin in patients with type 2 diabetes.

Not to be used in combination with other GLP-1 receptor agonist products.

May increase the risk of hypoglycemia when used with insulin or sulfonylureas in patients with type 2 diabetes.

Not recommended during pregnancy or breastfeeding.

Women of childbearing potential should use contraception during treatment.

Should be discontinued at least 2 months before a planned pregnancy.

Not recommended for patients under 18 years of age.

What are the Ingredients in Wegovy?

Active ingredient:

Semaglutide (human GLP-1 analogue produced in Saccharomyces cerevisiae cells by recombinant DNA technology)

Concentration varies by pen:

0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg semaglutide per dose

Inactive ingredients:

Disodium phosphate dihydrate

Sodium chloride

Hydrochloric acid (for pH adjustment)

Sodium hydroxide (for pH adjustment)

Water for injections

Additional ingredients in FlexTouch pens:

Propylene glycol

Phenol

Product Details

Product Form: Solution for injection in pre-filled pens

Available in two pen types:

Single-use pre-filled pens (one dose per pen)

FlexTouch pre-filled pens (four doses per pen)

Dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg

Storage:

Store in refrigerator (2°C–8°C). Do not freeze.

Single-use pens may be stored unrefrigerated for up to 28 days at temperatures not above 30°C.

FlexTouch pens after first use: May be stored for up to 6 weeks below 30°C or in a refrigerator (2°C–8°C).